Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026)
Puma Biotechnology (PBYI) posted EBITDA Margin of 8.54% for Q1 2026, down 137.68% on a QoQ basis from 22.67% in Q4 2025, and down 1720.0% year-over-year from 0.53% in Q1 2025.
Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology's EBITDA Margin history runs 10 years deep, the most recent figure standing at 8.54% for Q1 2026.
- Quarterly EBITDA Margin fell 1720.0% year-over-year to 8.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.98% (down 303.0% YoY) and the FY2025 annual result came in at 16.33%, up 290.0% from the prior year.
- EBITDA Margin was 8.54% for Q1 2026 at Puma Biotechnology, down from 22.67% in the prior quarter.
- Across five years, EBITDA Margin topped out at 27.41% in Q3 2024 and bottomed at 8.54% in Q1 2026.
- A 5-year average of 10.61% and a median of 11.43% in 2022 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 5142 bps in 2022, while the deepest fall reached 2216 bps in 2022.
- Puma Biotechnology's EBITDA Margin stood at 11.43% in 2022, then jumped by 79 bps to 20.5% in 2023, then rose by 10 bps to 22.62% in 2024, then climbed by 0 bps to 22.67% in 2025, then plunged by 138 bps to 8.54% in 2026.
- Business Quant data shows PBYI's EBITDA Margin at 8.54% in Q1 2026, 22.67% in Q4 2025, and 17.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn | -8.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.54% |
| Dec 31, 2025 | 22.67% |
| Sep 30, 2025 | 17.57% |
| Jun 30, 2025 | 12.66% |
| Mar 31, 2025 | 8.66% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 27.41% |
| Jun 30, 2024 | -4.63% |
| Mar 31, 2024 | -5.25% |
| Dec 31, 2023 | 20.50% |
| Sep 30, 2023 | 15.30% |
| Jun 30, 2023 | 8.96% |
| Mar 31, 2023 | 8.27% |
| Dec 31, 2022 | 11.43% |
| Sep 30, 2022 | 4.19% |
| Jun 30, 2022 | 20.26% |
| Mar 31, 2022 | -1.63% |
| Dec 31, 2021 | 12.34% |
| Sep 30, 2021 | -19.36% |
| Jun 30, 2021 | -31.16% |